Show Summary Details
Page of

Evidence-based treatment of lupus nephritis 

Evidence-based treatment of lupus nephritis
Chapter:
Evidence-based treatment of lupus nephritis
Author(s):

Wai Y. Tse

and Dwomoa Adu

DOI:
10.1093/med/9780199579655.003.0032
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 March 2020

1. A summary of the recommendations of the management of SLE is shown in Table 5.1.

2. Complications of drug treatment account for much of the morbidity that develops in SLE, in particular complications of high-dose or chronic corticosteroids (infection, osteonecrosis, osteoporosis, coronary artery disease) and cyclophosphamide (infection, sterility, bladder toxicity and malignancy).

3. It is encouraging that mycophenolate mofetil has a less toxic side effect profile than cyclo-phosphamide.

4. The risk of infections is substantial in patients taking corticosteroids and immuno-suppressants.

5. Regular clinical review of the patient's condition, together with laboratory tests and urinalysis to detect marrow depression, disease activity or progressive disease is mandatory in the management of these patients.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.